Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E.
Lisbon, Portugal
Brief biography of partner
The Portuguese Oncology Institute of Lisbon Francisco Gentil E.P.E. (IPO Lisbon) is a leading oncology hospital with over a century of experience in cancer care, research, and education. It provides highly specialised oncology services and is certified by the Ministry of Health as a National Reference Center for the treatment of several cancers, including esophageal, rectal, pediatric, testicular, and soft tissue and bone sarcomas. IPO Lisbon is accredited by the Organisation of European Cancer Institutes and is part of the European Reference Networks EURACAN, PAEDCAN, and GENTURIS. The Institute is also a founding member of the research unit iNOVA4Health and the Associate Laboratory LS4FUTURE.
The Institute has also contributed to the development of several procedures in cancer diagnosis and treatment. Each year, we assist around 70,000 patients, delivering more than 330,000 consultations, 44,000 chemotherapy treatments, 76,000 radiotherapy treatments, and approximately 9,000 surgeries.
Role in the project
IPO Lisbon brings expertise in assessing risk perception and psychological distress following genetic testing. It serves as the medical coordinator of Clinical Study A (CSA) and participates as a clinical site in both Clinical Study A and Clinical Study B (CSB).
In CSA, IPO Lisbon will implement multifactorial ovarian cancer (OC) risk stratification for individuals identified as potentially at risk based on family history criteria. In CSB, IPO Lisbon will undertake laboratory work and contribute to data analysis, supporting the upscaling and validation of the DISARM liquid biopsy detection technologies.